Table 1.
Successful completed phase III trials with anti-VEGF pathway agents
| Combined with | Tumor (setting) | ↑ PFS? | ↑OS? | Trial identifier |
|---|---|---|---|---|
| Bevacizumab | ||||
| FOLFIRI | CRC (1st) | Yes | Yes* | AVF210796 |
| FOLFOX or XELOX | CRC (1st) | Yes* | Yes | NO1696615 |
| FOLFOX | CRC (2nd) | Yes | Yes* | E320097 |
| Paclitaxol | MBC (1st) | Yes* | No | E210098 |
| Docetaxol | MBC (1st) | Yes* | NA | AVADO99 |
| Capecitabine and taxane or anthracycline | MBC (1st) | Yes* | No | Ribbon1100 |
| Chemotherapy‡ | MBC (2nd) | Yes* | NA | Ribbon2101 |
| Carboplatin and paclitaxel | NSCLC (1st) | Yes | Yes* | E4599102 |
| Cisplatin and gemcitabine | NSCLC (1st) | Yes* | No | AVAiL103 |
| Erlotinib | NSCLC (2nd) | Yes* | NA | ATLAS104 |
| Interferon-2α | RCC (1st) | Yes | No* | AVOREN105 |
| Interferon-2α | RCC (1st) | Yes | No* | CALGB90206106 |
| Carboplatin and paclitaxel | OC (1st) | Yes* | NA | GOG 021837 |
| Monotherapy | GBM (2nd)§ | Yes‖ | Yes‖ | AVF3708107 |
| Sunitinib | ||||
| Monotherapy | RCC (1st) | Yes* | Yes | NCT00083889108 |
| Monotherapy | GIST (2nd) | Yes¶ | NA | SUN 1112109 |
| Monotherapy | PIC (2nd) | Yes* | Yes | NCT00428597110 |
| Sorafenib | ||||
| Monotherapy | RCC (1st) | Yes | No*# | TARGET111 |
| Monotherapy | HCC (1st) | No | Yes* | SHARP112 |
| Pazopanib | ||||
| Monotherapy | RCC (1st and 2nd) | Yes* | NA | VEG105192113 |
| Vandetanib | ||||
| Docetaxol | NSCLC (2nd) | Yes* | NA | ZODIAC114 |
Primary end point.
Various chemotherapies including paclitaxel, protein-bound paclitaxel, docetaxel, gemcitabine, capecitabine, and vinorelbine.
A phase II trial.
Study evaluated the outcome of each arm relative to historical control.
Objective response rate improved.
Benefit seen with crossover.
Abbreviations: ↑, increased; 5-fluorouracil, 5-FU; CRC, colorectal cancer; FOLFOX, 5-FU, leucovorin and oxaliplatin; FOLFIRI, 5-FU, leucovorin and irinotecan; GBM, glioblastoma muliforme; GIST, gastrointestinal stromal tumors; HCC, hepatocellular carcinoma; MBC, metastatic breast cancer; NA, not available (pending, unknown or not reported); NSCLC, non-small-cell lung cancer; OC, ovarian cancer; OS, overall survival; PFS, progression-free survival; PIC, pancreatic islet cell; RCC, renal cell carcinoma; XELOX, capecitabine and oxaliplatin.